Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Support

This activity is supported by an educational grant from Exelixis, Inc.

Cases and Conversations™ in Advanced Renal Cell Carcinoma: Leveraging Landmark Evidence and Shared Decision-making to Chart Personalized Care Trajectories

Release Date: July 13, 2021
Expiration Date: July 13, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in renal cell carcinoma (RCC) treatment and clinical research. This symposium provides oncologists with expert perspectives on the pathobiology of RCC subtypes, the efficacy of novel and emerging treatment options for patients with RCC throughout the disease spectrum including immunotherapies and targeted agents, and the identification and management of treatment-related adverse events. Case studies will bring together the elements of clinical trial data and decision-making in clinical practice and provide oncologists with insight into how the experts approach treatment decisions for patients with RCC. An interview with the CEO from the Kidney Cancer Association (KCA) will review methods for patient advocacy as well as the resources available from the KCA.

This educational activity is an archive of a live virtual symposium held on Thursday, June 17, 2021.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Exelixis, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists interested in the treatment of renal cell carcinoma. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with renal cell carcinoma will be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Review the pathobiology of RCC and how this provides the rationale for targeted therapies and immunotherapies, as single agents and in combination regimens.
  • Discuss emerging evidence from clinical trials investigating treatment options for patients with advanced RCC and how these data impact treatment decision-making across lines of therapy for individual patients.
  • Implement strategies for preventing and/or managing treatment-related adverse events associated with systemic regimens used to treat advanced RCC.
  • Individualize systemic treatment selection for patients with advanced/metastatic RCC, taking into consideration biomarkers, disease characteristics, comorbidities, and patient preferences, and quality of life in addition to efficacy and safety data.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

Program Chair

Robert A. Figlin, MD, FACP
Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology-Oncology
Professor of Medicine and Biomedical Sciences
Deputy Director, Cedars-Sinai Cancer
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

Disclosures: Robert A. Figlin has no relevant financial relationships with ineligible companies.


Daniel Heng, MD, MPH, FRCPC
Daniel Heng, MD, MPH, FRCPC
Clinical Professor and Head, Medical Oncology
University of Calgary
Section Chief, Medical Oncology
Staff Medical Oncologist
Tom Baker Cancer Centre
Alberta, Canada

Disclosures: Grant Research Support: Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Merck, Novartis, Pfizer; Consultant: Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Merck, Novartis, Pfizer.

Eric Jonasch, MD
Eric Jonasch, MD
Professor, Department of Genitourinary Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: Aravive, Merck & Co, Novartis; Consultant: Aravive, AVEO Oncology, Calithera Biosciences, Eisai, Exelixis, Ipsen Biopharmaceuticals, Merck & Co, NiKang Therapeutics, Novartis, Pfizer.

Rana R. McKay, MD
Rana R. McKay, MD
Associate Professor of Medicine
University of California San Diego
La Jolla, CA

Disclosures: Grant Research Support: Bayer Healthcare, Pfizer, Tempus; Consultant: AstraZeneca, Bayer Healthcare, Bristol Myers Squibb, Calithera Biosciences, Dendreon, Exelixis, Janssen Pharmaceuticals, Merck & Co, Novartis, Pfizer, Sanofi, Tempus, Vividion Therapeutics.

Sumanta K. Pal, MD
Sumanta K. Pal, MD
Clinical Professor
Department of Medical Oncology & Therapeutics Research
City of Hope Comprehensive Cancer Center
SWOG RCC Translational Medicine Chair
Duarte, CA

Disclosures: Sumanta K. Pal has no relevant financial relationships with ineligible companies.

Gretchen E. Vaughan
Gretchen E. Vaughan
President and CEO
Kidney Cancer Association (KCA)
Houston, TX

Disclosures: Gretchen E. Vaughan has no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By